Skip to main content
Top
Published in: Molecular Cancer 1/2007

Open Access 01-12-2007 | Research

Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma

Authors: Emmanuel Rousseau, Thomas Palm, Francesco Scaravilli, Marie-Magdeleine Ruchoux, Dominique Figarella-Branger, Isabelle Salmon, David Ellison, Catherine Lacroix, Françoise Chapon, Jacqueline Mikol, Miikka Vikkula, Catherine Godfraind

Published in: Molecular Cancer | Issue 1/2007

Login to get access

Abstract

Ependymal tumors constitute a clinicopathologically heterogeneous group of brain tumors. They vary in regard to their age at first symptom, localization, morphology and prognosis. Genetic data also suggests heterogeneity. We define a newly recognized subset of ependymal tumors, the trisomy 19 ependymoma. Histologically, they are compact lesions characterized by a rich branched capillary network amongst which tumoral cells are regularly distributed. When containing clear cells they are called clear cell ependymoma. Most trisomy 19 ependymomas are supratentorial WHO grade III tumors of the young. Genetically, they are associated with trisomy 19, and frequently with a deletion of 13q21.31-31.2, three copies of 11q13.3-13.4, and/or deletions on chromosome 9. These altered chromosomal regions are indicative of genes and pathways involved in trisomy 19 ependymoma tumorigenesis. Recognition of this genetico-histological entity allows better understanding and dissection of ependymal tumors.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kleihues P, Cavenee WK, : Pathology & Genetics. Tumours of the Nervous System. 2000, Lyon: IARC Press, Kleihues P, Cavenee WK, : Pathology & Genetics. Tumours of the Nervous System. 2000, Lyon: IARC Press,
2.
go back to reference Ohgaki H, Kleihues P: Epidemiology and etiology of gliomas. Acta Neuropathol (Berl). 2005, 109: 93-108. 10.1007/s00401-005-0991-yCrossRef Ohgaki H, Kleihues P: Epidemiology and etiology of gliomas. Acta Neuropathol (Berl). 2005, 109: 93-108. 10.1007/s00401-005-0991-yCrossRef
3.
go back to reference Hirose Y, Aldape K, Bollen A, James CD, Brat D, Lamborn K, Berger M, Feuerstein BG: Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol. 2001, 158: 1137-1143.PubMedCentralCrossRefPubMed Hirose Y, Aldape K, Bollen A, James CD, Brat D, Lamborn K, Berger M, Feuerstein BG: Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol. 2001, 158: 1137-1143.PubMedCentralCrossRefPubMed
4.
go back to reference Dyer S, Prebble E, Davison V, Davies P, Ramani P, Ellison D, Grundy R: Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. Am J Pathol. 2002, 161: 2133-2141.PubMedCentralCrossRefPubMed Dyer S, Prebble E, Davison V, Davies P, Ramani P, Ellison D, Grundy R: Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. Am J Pathol. 2002, 161: 2133-2141.PubMedCentralCrossRefPubMed
5.
go back to reference Carter M, Nicholson J, Ross F, Crolla J, Allibone R, Balaji V, Perry R, Walker D, Gilbertson R, Ellison DW: Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer. 2002, 86: 929-939. 10.1038/sj.bjc.6600180PubMedCentralCrossRefPubMed Carter M, Nicholson J, Ross F, Crolla J, Allibone R, Balaji V, Perry R, Walker D, Gilbertson R, Ellison DW: Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer. 2002, 86: 929-939. 10.1038/sj.bjc.6600180PubMedCentralCrossRefPubMed
6.
go back to reference Rajaram V, Leuthardt EC, Singh PK, Ojemann JG, Brat DJ, Prayson RA, Perry A: 9p21 and 13q14 dosages in ependymomas. A clinicopathologic study of 101 cases. Mod Pathol. 2004, 17: 9-14. 10.1038/modpathol.3800029CrossRefPubMed Rajaram V, Leuthardt EC, Singh PK, Ojemann JG, Brat DJ, Prayson RA, Perry A: 9p21 and 13q14 dosages in ependymomas. A clinicopathologic study of 101 cases. Mod Pathol. 2004, 17: 9-14. 10.1038/modpathol.3800029CrossRefPubMed
7.
go back to reference Rousseau E, Ruchoux MM, Scaravilli F, Chapon F, Vinchon M, De Smet C, Godfraind C, Vikkula M: CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathol Appl Neurobiol. 2003, 29: 574-583. 10.1046/j.0305-1846.2003.00505.xCrossRefPubMed Rousseau E, Ruchoux MM, Scaravilli F, Chapon F, Vinchon M, De Smet C, Godfraind C, Vikkula M: CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathol Appl Neurobiol. 2003, 29: 574-583. 10.1046/j.0305-1846.2003.00505.xCrossRefPubMed
8.
go back to reference Lassmann S, Weis R, Makowiec F, Roth J, Danciu M, Hopt U, Werner M: Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas. J Mol Med. 2007, 85: 289-300. 10.1007/s00109-006-0126-5CrossRef Lassmann S, Weis R, Makowiec F, Roth J, Danciu M, Hopt U, Werner M: Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas. J Mol Med. 2007, 85: 289-300. 10.1007/s00109-006-0126-5CrossRef
9.
go back to reference Johnson NA, Hamoudi RA, Ichimura K, Liu L, Pearson DM, Collins VP, Du MQ: Application of array CGH on archival formalin-fixed paraffin-embedded tissues including small numbers of microdissected cells. Lab Invest. 2006, 86: 968-978. 10.1038/labinvest.3700441PubMedCentralCrossRefPubMed Johnson NA, Hamoudi RA, Ichimura K, Liu L, Pearson DM, Collins VP, Du MQ: Application of array CGH on archival formalin-fixed paraffin-embedded tissues including small numbers of microdissected cells. Lab Invest. 2006, 86: 968-978. 10.1038/labinvest.3700441PubMedCentralCrossRefPubMed
10.
go back to reference Little SE, Vuononvirta R, Reis-Filho JS, Natrajan R, Iravani M, Fenwick K, Mackay A, Ashworth A, Pritchard-Jones K, Jones C: Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. Genomics. 2006, 87: 298-306. 10.1016/j.ygeno.2005.09.019CrossRefPubMed Little SE, Vuononvirta R, Reis-Filho JS, Natrajan R, Iravani M, Fenwick K, Mackay A, Ashworth A, Pritchard-Jones K, Jones C: Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. Genomics. 2006, 87: 298-306. 10.1016/j.ygeno.2005.09.019CrossRefPubMed
11.
go back to reference Mohapatra G, Betensky RA, Miller ER, Carey B, Gaumont LD, Engler DA, Louis DN: Glioma test array for use with formalin-fixed, paraffin-embedded tissue: array comparative genomic hybridization correlates with loss of heterozygosity and fluorescence in situ hybridization. J Mol Diagn. 2006, 8: 268-276. 10.2353/jmoldx.2006.050109 10.2353/jmoldx.2006.050109PubMedCentralCrossRefPubMed Mohapatra G, Betensky RA, Miller ER, Carey B, Gaumont LD, Engler DA, Louis DN: Glioma test array for use with formalin-fixed, paraffin-embedded tissue: array comparative genomic hybridization correlates with loss of heterozygosity and fluorescence in situ hybridization. J Mol Diagn. 2006, 8: 268-276. 10.2353/jmoldx.2006.050109 10.2353/jmoldx.2006.050109PubMedCentralCrossRefPubMed
13.
go back to reference Kawano N, Yagishita S, Komatsu K, Suwa T, Oka H, Utsuki S, Fujii K: Cerebellar clear cell ependymoma mimicking hemangioblastoma: its clinical and pathological features. Surg Neurol. 1999, 51: 281-287. discussion 287–288.. 10.1016/S0090-3019(97)00502-8CrossRefPubMed Kawano N, Yagishita S, Komatsu K, Suwa T, Oka H, Utsuki S, Fujii K: Cerebellar clear cell ependymoma mimicking hemangioblastoma: its clinical and pathological features. Surg Neurol. 1999, 51: 281-287. discussion 287–288.. 10.1016/S0090-3019(97)00502-8CrossRefPubMed
14.
go back to reference Koperek O, Gelpi E, Birner P, Haberler C, Budka H, Hainfellner JA: Value and limits of immunohistochemistry in differential diagnosis of clear cell primary brain tumors. Acta Neuropathol (Berl). 2004, 108: 24-30. 10.1007/s00401-004-0856-9CrossRef Koperek O, Gelpi E, Birner P, Haberler C, Budka H, Hainfellner JA: Value and limits of immunohistochemistry in differential diagnosis of clear cell primary brain tumors. Acta Neuropathol (Berl). 2004, 108: 24-30. 10.1007/s00401-004-0856-9CrossRef
15.
go back to reference Kawano N, Yada K, Yagishita S: Clear cell ependymoma. A histological variant with diagnostic implications. Virchows Arch A Pathol Anat Histopathol. 1989, 415: 467-472. 10.1007/BF00747748CrossRefPubMed Kawano N, Yada K, Yagishita S: Clear cell ependymoma. A histological variant with diagnostic implications. Virchows Arch A Pathol Anat Histopathol. 1989, 415: 467-472. 10.1007/BF00747748CrossRefPubMed
16.
go back to reference Min KW, Scheithauer BW: Clear cell ependymoma: a mimic of oligodendroglioma: clinicopathologic and ultrastructural considerations. Am J Surg Pathol. 1997, 21: 820-826. 10.1097/00000478-199707000-00010CrossRefPubMed Min KW, Scheithauer BW: Clear cell ependymoma: a mimic of oligodendroglioma: clinicopathologic and ultrastructural considerations. Am J Surg Pathol. 1997, 21: 820-826. 10.1097/00000478-199707000-00010CrossRefPubMed
17.
go back to reference Hasselblatt M, Paulus W: Sensitivity and specificity of epithelial membrane antigen staining patterns in ependymomas. Acta Neuropathol (Berl). 2003, 106: 385-388. 10.1007/s00401-003-0752-8CrossRef Hasselblatt M, Paulus W: Sensitivity and specificity of epithelial membrane antigen staining patterns in ependymomas. Acta Neuropathol (Berl). 2003, 106: 385-388. 10.1007/s00401-003-0752-8CrossRef
18.
go back to reference Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994, 145: 1175-1190.PubMedCentralPubMed Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994, 145: 1175-1190.PubMedCentralPubMed
19.
go back to reference Perry A, Fuller CE, Banerjee R, Brat DJ, Scheithauer BW: Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci. 2003, 8: a1-9. 10.2741/896 10.2741/896CrossRefPubMed Perry A, Fuller CE, Banerjee R, Brat DJ, Scheithauer BW: Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci. 2003, 8: a1-9. 10.2741/896 10.2741/896CrossRefPubMed
20.
go back to reference Rickert CH, Korshunov A, Paulus W: Chromosomal imbalances in clear cell ependymomas. Mod Pathol. 2006, 19: 958-962. 10.1038/modpathol.3800614CrossRefPubMed Rickert CH, Korshunov A, Paulus W: Chromosomal imbalances in clear cell ependymomas. Mod Pathol. 2006, 19: 958-962. 10.1038/modpathol.3800614CrossRefPubMed
21.
go back to reference Fouladi M, Helton K, Dalton J, Gilger E, Gajjar A, Merchant T, Kun L, Newsham I, Burger P, Fuller C: Clear cell ependymoma: a clinicopathologic and radiographic analysis of 10 patients. Cancer. 2003, 98: 2232-2244. 10.1002/cncr.11783CrossRefPubMed Fouladi M, Helton K, Dalton J, Gilger E, Gajjar A, Merchant T, Kun L, Newsham I, Burger P, Fuller C: Clear cell ependymoma: a clinicopathologic and radiographic analysis of 10 patients. Cancer. 2003, 98: 2232-2244. 10.1002/cncr.11783CrossRefPubMed
22.
go back to reference Weber T, Weber RG, Kaulich K, Actor B, Meyer-Puttlitz B, Lampel S, Buschges R, Weigel R, Deckert-Schluter M, Schmiedek P: Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type. Brain Pathol. 2000, 10: 73-84.CrossRefPubMed Weber T, Weber RG, Kaulich K, Actor B, Meyer-Puttlitz B, Lampel S, Buschges R, Weigel R, Deckert-Schluter M, Schmiedek P: Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type. Brain Pathol. 2000, 10: 73-84.CrossRefPubMed
23.
go back to reference Mullaney BP, Ng VL, Herndier BG, McGrath MS, Pallavicini MG: Comparative genomic analyses of primary effusion lymphoma. Arch Pathol Lab Med. 2000, 124: 824-826.PubMed Mullaney BP, Ng VL, Herndier BG, McGrath MS, Pallavicini MG: Comparative genomic analyses of primary effusion lymphoma. Arch Pathol Lab Med. 2000, 124: 824-826.PubMed
24.
go back to reference Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9CrossRefPubMed Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9CrossRefPubMed
25.
go back to reference Dunaief JL, Strober BE, Guha S, Khavari PA, Alin K, Luban J, Begemann M, Crabtree GR, Goff SP: The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell. 1994, 79: 119-130. 10.1016/0092-8674(94)90405-7CrossRefPubMed Dunaief JL, Strober BE, Guha S, Khavari PA, Alin K, Luban J, Begemann M, Crabtree GR, Goff SP: The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell. 1994, 79: 119-130. 10.1016/0092-8674(94)90405-7CrossRefPubMed
26.
go back to reference Dasgupta P, Sun J, Wang S, Fusaro G, Betts V, Padmanabhan J, Sebti SM, Chellappan SP: Disruption of the Rb – Raf-1 interaction inhibits tumor growth and angiogenesis. Mol Cell Biol. 2004, 24: 9527-9541. 10.1128/MCB.24.21.9527-9541.2004PubMedCentralCrossRefPubMed Dasgupta P, Sun J, Wang S, Fusaro G, Betts V, Padmanabhan J, Sebti SM, Chellappan SP: Disruption of the Rb – Raf-1 interaction inhibits tumor growth and angiogenesis. Mol Cell Biol. 2004, 24: 9527-9541. 10.1128/MCB.24.21.9527-9541.2004PubMedCentralCrossRefPubMed
27.
go back to reference Weitzman JB, Fiette L, Matsuo K, Yaniv M: JunD protects cells from p53-dependent senescence and apoptosis. Mol Cell. 2000, 6: 1109-1119. 10.1016/S1097-2765(00)00109-XCrossRefPubMed Weitzman JB, Fiette L, Matsuo K, Yaniv M: JunD protects cells from p53-dependent senescence and apoptosis. Mol Cell. 2000, 6: 1109-1119. 10.1016/S1097-2765(00)00109-XCrossRefPubMed
28.
go back to reference Sumbayev VV, Yasinska IM: Role of MAP kinase-dependent apoptotic pathway in innate immune responses and viral infection. Scand J Immunol. 2006, 63: 391-400. 10.1111/j.1365-3083.2006.001764.xCrossRefPubMed Sumbayev VV, Yasinska IM: Role of MAP kinase-dependent apoptotic pathway in innate immune responses and viral infection. Scand J Immunol. 2006, 63: 391-400. 10.1111/j.1365-3083.2006.001764.xCrossRefPubMed
29.
go back to reference Trouche D, Le Chalony C, Muchardt C, Yaniv M, Kouzarides T: RB and hbrm cooperate to repress the activation functions of E2F1. Proc Natl Acad Sci USA. 1997, 94: 11268-11273. 10.1073/pnas.94.21.11268PubMedCentralCrossRefPubMed Trouche D, Le Chalony C, Muchardt C, Yaniv M, Kouzarides T: RB and hbrm cooperate to repress the activation functions of E2F1. Proc Natl Acad Sci USA. 1997, 94: 11268-11273. 10.1073/pnas.94.21.11268PubMedCentralCrossRefPubMed
30.
go back to reference Wang L, Baiocchi RA, Pal S, Mosialos G, Caligiuri M, Sif S: The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene. Mol Cell Biol. 2005, 25: 7953-7965. 10.1128/MCB.25.18.7953-7965.2005PubMedCentralCrossRefPubMed Wang L, Baiocchi RA, Pal S, Mosialos G, Caligiuri M, Sif S: The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene. Mol Cell Biol. 2005, 25: 7953-7965. 10.1128/MCB.25.18.7953-7965.2005PubMedCentralCrossRefPubMed
31.
go back to reference Menendez JA, Mehmi I, Griggs DW, Lupu R: The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr Relat Cancer. 2003, 10: 141-152. 10.1677/erc.0.0100141CrossRefPubMed Menendez JA, Mehmi I, Griggs DW, Lupu R: The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr Relat Cancer. 2003, 10: 141-152. 10.1677/erc.0.0100141CrossRefPubMed
32.
go back to reference Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, Bugelski P, Yan L: Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005, 65: 3193-3199.PubMed Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, Bugelski P, Yan L: Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005, 65: 3193-3199.PubMed
33.
go back to reference Gabison EE, Hoang-Xuan T, Mauviel A, Menashi S: EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie. 2005, 87: 361-368. 10.1016/j.biochi.2004.09.023CrossRefPubMed Gabison EE, Hoang-Xuan T, Mauviel A, Menashi S: EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie. 2005, 87: 361-368. 10.1016/j.biochi.2004.09.023CrossRefPubMed
34.
go back to reference Tang J, Hu G, Hanai J, Yadlapalli G, Lin Y, Zhang B, Galloway J, Bahary N, Sinha S, Thisse B: A critical role for calponin 2 in vascular development. J Biol Chem. 2006, 281: 6664-6672. 10.1074/jbc.M506991200CrossRefPubMed Tang J, Hu G, Hanai J, Yadlapalli G, Lin Y, Zhang B, Galloway J, Bahary N, Sinha S, Thisse B: A critical role for calponin 2 in vascular development. J Biol Chem. 2006, 281: 6664-6672. 10.1074/jbc.M506991200CrossRefPubMed
35.
go back to reference Yang Y, Goldstein BG, Chao HH, Katz JP: KLF4 and KLF5 regulate proliferation, apoptosis and invasion in esophageal cancer cells. Cancer Biol Ther. 2005, 4: 1216-1221.CrossRefPubMed Yang Y, Goldstein BG, Chao HH, Katz JP: KLF4 and KLF5 regulate proliferation, apoptosis and invasion in esophageal cancer cells. Cancer Biol Ther. 2005, 4: 1216-1221.CrossRefPubMed
42.
go back to reference Gross I, Bassit B, Benezra M, Licht JD: Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation. J Biol Chem. 2001, 276: 46460-46468. 10.1074/jbc.M108234200CrossRefPubMed Gross I, Bassit B, Benezra M, Licht JD: Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation. J Biol Chem. 2001, 276: 46460-46468. 10.1074/jbc.M108234200CrossRefPubMed
43.
go back to reference Yang X, Webster JB, Kovalenko D, Nadeau RJ, Zubanova O, Chen PY, Friesel R: Sprouty genes are expressed in osteoblasts and inhibit fibroblast growth factor-mediated osteoblast responses. Calcif Tissue Int. 2006, 78: 233-240. 10.1007/s00223-005-0231-4CrossRefPubMed Yang X, Webster JB, Kovalenko D, Nadeau RJ, Zubanova O, Chen PY, Friesel R: Sprouty genes are expressed in osteoblasts and inhibit fibroblast growth factor-mediated osteoblast responses. Calcif Tissue Int. 2006, 78: 233-240. 10.1007/s00223-005-0231-4CrossRefPubMed
44.
go back to reference Zhu N, Gu L, Findley HW, Chen C, Dong JT, Yang L, Zhou M: KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem. 2006, 281: 14711-14718. 10.1074/jbc.M513810200CrossRefPubMed Zhu N, Gu L, Findley HW, Chen C, Dong JT, Yang L, Zhou M: KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem. 2006, 281: 14711-14718. 10.1074/jbc.M513810200CrossRefPubMed
45.
go back to reference Banine F, Bartlett C, Gunawardena R, Muchardt C, Yaniv M, Knudsen ES, Weissman BE, Sherman LS: SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. Cancer Res. 2005, 65: 3542-3547. 10.1158/0008-5472.CAN-04-3554CrossRefPubMed Banine F, Bartlett C, Gunawardena R, Muchardt C, Yaniv M, Knudsen ES, Weissman BE, Sherman LS: SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. Cancer Res. 2005, 65: 3542-3547. 10.1158/0008-5472.CAN-04-3554CrossRefPubMed
46.
go back to reference Lukashova V, Zangen I, Kneitz S, Monoranu CM, Rutkowski S, Hinkes B, Vince GH, Huang B, Roggendorf W: Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival. Acta Neuropathol (Berl). 2007, 113: 325-337. 10.1007/s00401-006-0190-5CrossRef Lukashova V, Zangen I, Kneitz S, Monoranu CM, Rutkowski S, Hinkes B, Vince GH, Huang B, Roggendorf W: Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival. Acta Neuropathol (Berl). 2007, 113: 325-337. 10.1007/s00401-006-0190-5CrossRef
47.
go back to reference Singh PK, Gutmann DH, Fuller CE, Newsham IF, Perry A: Differential involvement of protein 4.1 family members DAL-1 and NF2 in intracranial and intraspinal ependymomas. Mod Pathol. 2002, 15: 526-531. 10.1038/modpathol.3880558CrossRefPubMed Singh PK, Gutmann DH, Fuller CE, Newsham IF, Perry A: Differential involvement of protein 4.1 family members DAL-1 and NF2 in intracranial and intraspinal ependymomas. Mod Pathol. 2002, 15: 526-531. 10.1038/modpathol.3880558CrossRefPubMed
48.
go back to reference Michalowski MB, de Fraipont F, Michelland S, Entz-Werle N, Grill J, Pasquier B, Favrot MC, Plantaz D: Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet. 2006, 166: 74-81. 10.1016/j.cancergencyto.2005.09.004CrossRefPubMed Michalowski MB, de Fraipont F, Michelland S, Entz-Werle N, Grill J, Pasquier B, Favrot MC, Plantaz D: Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet. 2006, 166: 74-81. 10.1016/j.cancergencyto.2005.09.004CrossRefPubMed
50.
go back to reference Godfraind C, Rousseau E, Ruchoux MM, Scaravilli F, Vikkula M: Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. Neuropathol Appl Neurobiol. 2003, 29: 462-471. 10.1046/j.1365-2990.2003.00484.xCrossRefPubMed Godfraind C, Rousseau E, Ruchoux MM, Scaravilli F, Vikkula M: Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. Neuropathol Appl Neurobiol. 2003, 29: 462-471. 10.1046/j.1365-2990.2003.00484.xCrossRefPubMed
51.
go back to reference Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A, Kurokawa M, Chiba S, Bailey DK, Kennedy GC, Ogawa S: A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res. 2005, 65: 6071-6079. 10.1158/0008-5472.CAN-05-0465CrossRefPubMed Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A, Kurokawa M, Chiba S, Bailey DK, Kennedy GC, Ogawa S: A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res. 2005, 65: 6071-6079. 10.1158/0008-5472.CAN-05-0465CrossRefPubMed
52.
go back to reference Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C: dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics. 2004, 20: 1233-1240. 10.1093/bioinformatics/bth069CrossRefPubMed Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C: dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics. 2004, 20: 1233-1240. 10.1093/bioinformatics/bth069CrossRefPubMed
Metadata
Title
Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma
Authors
Emmanuel Rousseau
Thomas Palm
Francesco Scaravilli
Marie-Magdeleine Ruchoux
Dominique Figarella-Branger
Isabelle Salmon
David Ellison
Catherine Lacroix
Françoise Chapon
Jacqueline Mikol
Miikka Vikkula
Catherine Godfraind
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2007
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-6-47

Other articles of this Issue 1/2007

Molecular Cancer 1/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine